spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Norwich Pharmaceuticals Announces Significant Business Growth

Norwich Clinical Services

Increased project volume, new clients propel revenues and expanded services

Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry, announced today that the company has achieved significant business growth in first quarter, 2012 as compared to the same period in 2011. Key growth areas include volume of projects currently in development and commercial production, scope of projects expanded into multiple service categories, and total value of new business won.

"Norwich’s growth is a direct result of our ability to maintain high quality standards while providing expertise and flexibility for both product development and commercial manufacturing," said Terry Novak, president of Norwich. "During the past year, Norwich has expanded our capabilities to meet the market demands for smaller scale development services. Providing expertise in novel, solid dose formulations, we have been able to offer services to new clientele while increasing our repeat business rate with current customers."

New client awards in the first quarter accounted for 33% of all Norwich projects while repeat business in Q1, 2012 more than doubled as compared to the same period last year. The total value of new projects increased 25%. Several of the new projects will utilize Norwich services for potent compounds, low humidity, bead extrusion, tablet coating, formulation development, BA/BE studies, and global packaging and distribution.

About Norwich Pharmaceuticals

Norwich is a full-service contract development and manufacturing provider for Rx and OTC pharmaceuticals. Norwich applies more than 120 years of experience and an unparalleled compliance record to offer customers greater flexibility, resources and speed that result in a streamlined progression from product development to scale-up and commercial manufacturing through clinical services. Visit www.norwichpharma.com for more information.

phone +1 888 674 7979
email info@norwichpharma.com
web www.norwichpharma.com
email 6826 State Highway 12, Norwich, NY 13815, UNITED STATES
 
Print this page
Send to a friend
   
spacer
News and Press Releases

RSA to provide benchmark for Executive Interims Survey research to provide data intelligence

London, 25 November 2014: RSA, the leading global Life Sciences Executive Search and Executive Interims specialist, today launched a survey which seeks to explore issues around Interim placements in the life sciences sector including remuneration for Executive Interims, reasons for Interim engagement and operating models. The reason for the survey is to refine the understanding and value of Executive Interims in today’s competitive and changing market. To access the survey please go to: http://bit.ly/1tg8tLC
More info >>


White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

Industry Events

Adaptive Designs in Clinical Trials

20-21 April 2015, Marriott Regents Park Hotel, London, UK

Now in its 7th year, SMi is pleased to announce their 2015 agenda for Adaptive Designs in Clinical Trials taking place on 20th & 21stApril 2015. The conference continues to draw high level speakers from around the globe who are steering the innovative climate of adaptive designs to improve clinical trials. 
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement